COMMUNIQUÉS West-GlobeNewswire

ALK launches new growth strategy and 2028 financial ambitions
03/06/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in [...]
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
03/06/2024
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1 [...]
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03/06/2024
Coverage policy determination initiated with 5 Medicare MACs for HeartFlow's AI-QCT revolutionizing cardiovascular care for patients MOUNTAIN VIEW, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in [...]
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
03/06/2024
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of [...]
CenTrak Announces Partnership with The Leapfrog Group
03/06/2024
Partner Advisory Committee Membership Demonstrates Enhanced Commitment to Healthcare Safety NEWTOWN, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- CenTrak , the leader in real-time location technology solutions, announces its [...]
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
03/06/2024
Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, [...]
Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases
03/06/2024
Saint-Herblain (France), 3 juin 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que les résultats de deux essais cliniques de Phase 2 sur le candidat [...]
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03/06/2024
Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology Collaboration designed to deliver immunology and [...]
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
03/06/2024
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on pharmacokinetics of morning and [...]
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
03/06/2024
HENDERSON, Nev., June 03, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA ) introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good [...]
Novo Nordisk A/S - share repurchase programme
03/06/2024
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
03/06/2024
Ori LEAP partner CTMC shares biological results demonstrating new manufacturing platform can accelerate cell and gene therapy development LONDON and HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Ori Biotech Ltd. (Ori), a [...]
Aeterna Zentaris and Ceapro Complete Merger Transaction
03/06/2024
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative [...]
Aeterna Zentaris and Ceapro Complete Merger Transaction
03/06/2024
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative [...]
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
03/06/2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the [...]
Transactions in Connection with Share Buy-back Program
03/06/2024
Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The [...]
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
03/06/2024
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid [...]
BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related Instrumentation
03/06/2024
The state-of-the-art instrumentation will support and accelerate BioPharmaSpec’s clients’ efforts in successful biologics product development MALVERN, Pa. and ST. SAVIOUR, Jersey, June 03, 2024 (GLOBE NEWSWIRE) -- [...]
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
03/06/2024
Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics MIAMI, June 03 [...]

Pages